Decision Making for Cardiovascular Therapy in Adults with Mild Cognitive Impairment

a MiCDA Research Project Description

Investigators: Deborah Levine, Kenneth M. Langa, Brahmajee K. Nallamothu, Lewis B. Morgenstern, Darin Zahuranec, Andrzej T. Galecki

Funding: National Institute on Aging, 2016-2021 (1 R01 AG 051827 01)

There is a fundamental gap in understanding how mild cognitive impairment (MCI) influences treatment and decision making for serious illnesses, like cardiovascular disease (CVD), in older patients. Poor understanding of clinical decision making is a critical barrier to the design of interventions to improve the quality and patient-centeredness of CVD care of in older patients with MCI. The long-term goal is to develop, test, and disseminate interventions to improve the quality and patient-centeredness of CVD care in the large and growing population of older patients with MCI. The objective of this application is to improve our understanding of clinical decision making for the two most common CVD events in patients with mild cognitive impairment: acute myocardial infarction (AMI) and acute ischemic stroke. AMI and acute ischemic stroke are excellent models of serious, acute illnesses with a wide range of effective therapies for acute management, rehabilitation, and secondary prevention. Our central hypothesis is that older adults with MCI are undertreated for CVD because patients and physicians overestimate their risk of dementia and underestimate their risk of CVD. This hypothesis has been formulated on the basis of preliminary data from the applicants? pilot research. The rationale for the proposed research is that understanding how patient preferences and physician recommendations contribute to underuse of CVD treatments in patients with MCI has the potential to translate into targeted interventions aimed to improve the quality and patient-centeredness of care, resulting in new and innovative approaches to the treatment of CVD and other serious, acute illnesses in adults with MCI. Guided by strong preliminary data, this hypothesis will be tested by pursuing two specific aims: 1) Compare rates of AMI and stroke treatment between patients with MCI and patients with normal cognition and determine differences in clinical outcomes associated with treatment differences; and 2) Determine the influence of MCI on patient preferences and physician recommendations for AMI and stroke treatment. Under the first aim, a health services research approach, which has been established as feasible in the applicants? hands, will be used to quantify the extent, predictors, and outcomes of treatment differences for AMI and acute ischemic stroke in older patients with MCI. Under the second aim, a multi-center, mixed-methods approach, which also has been proven as feasible in the applicants? hands, will be used to determine the influence of MCI on patient preferences and physician recommendations for AMI and stroke treatment. This research proposal is innovative because it represents a new and substantially different way of addressing the important public health problem of enhancing the health of older adults by determining the extent and causes of underuse of effective CVD treatments in those with MCI. The proposed research is significant because it is expected to vertically advance and expand understanding of how MCI influences treatment and decision making for AMI and ischemic stroke in older patients. Ultimately, such knowledge has the potential to inform the development of targeted interventions that will help to reduce CVD-related disability in older Americans.

Research Signature Theme:

Health and well-being in later life: Disability